Why ImmunityBio Stock Is Soaring Again Today
The Motley Fool
by newsfeedback@fool.com (Josh Kohn-Lindquist)February 23, 2026
AI-Generated Deep Dive Summary
Shares of ImmunityBio (NASDAQ: IBRX) are surging 16% as of noon ET on Monday following the release of its fourth-quarter earnings report. The company, a leader in cancer immunotherapy, reported impressive growth for its flagship product Anktiva, which saw a staggering 700% year-over-year increase in sales in 2025 and a 20% quarter-over-quarter rise in Q4. While the company is still operating at a loss with an earnings per share (EPS) of $0.06 in Q4, this marks the third consecutive quarter of improving profitability, signaling strong momentum for ImmunityBio.
The article highlights how ImmunityBio's innovative Cancer BioShield platform and Anktiva biologic product work by stimulating natural killer cells, cytotoxic T cells, and memory T cells to help patients fight various cancers. Currently, the majority of ImmunityBio's revenue comes from U.S. sales of Anktiva, which is used to treat bladder cancer cases that have not responded to the Bacille Calmette-Guérin (BCG) vaccine. However, the company is expanding rapidly, with its focus on developing treatments for a growing number of cancers and diseases.
For finance enthusiasts, Imm
Verticals
financeinvesting
Originally published on The Motley Fool on 2/23/2026